Agenus Inc's Income per employee fell in the second quarter 2026 on a trailing twelve month basis to $ 1,135,037, but the productivity of Agenus Inc's 81 employees remained above the company average. The Healthcare sector has seen employees of 8 other companies achieving higher income per employee. While Agenus Inc's total ranking has deteriorated compared to the previous quarter from 247 to 248.
Overview of Agenus in Immuno-Oncology Agenus Inc. (Nasdaq: AGEN), based in Lexington, Massachusetts, is making significant strides in the field of immuno-oncology, positioning itself as a frontrunner in cancer treatment innovations. Known for its cutting-edge research and development, Agenus is actively involved in designing therapies aimed at enhancing immune response against cancer cells. Participation in Precision Oncology Conference Agenus has recently announced its participation in the B. Riley Securities Precision Oncology and Radiopharma Investor Conference in New York on February 28, 2025. The company will contribute to an influential panel discussion led by Robin Taylor, Ph.D. Chief Commercial Officer. The session,
: Agenus Inc. an innovative leader in the field of immuno-oncology, has recently showcased compelling data regarding their investigational immunotherapeutics, botensilimab (BOT) and balstilimab (BAL), at major oncology meetings. Emphasizing their synergistic potential in treating gastric and MSS colorectal cancers, these findings mark significant advancements in cancer treatment approaches specifically targeting immune-resistant tumors.At the American Association for Cancer Research (AACR) Immuno-Oncology Annual Meeting in Los Angeles, Agenus Inc. presented new translational data from an ongoing Phase 2 study that evaluates the efficacy of BOT and BAL in combination with MiNK Therapeutics’ agenT-797. This combination therapy utilizes the unique mechanism of the allogeneic invariant natural killer T (iNKT) cells, aiming to enhance immune response against gastric cancer, a malignancy associated with high mortality rates and limited treatment options.
Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
